[Outcomes and the role of adjuvant therapy of limited stage small cell lung cancer undergoing surgical treatment].

To investigate the outcomes of limited stage small cell lung cancer (L-SCLC) undergoing surgical therapy and to explore the value of adjuvant therapy for those patients. A retrospective analysis was initialed for the L-SCLC patients who underwent the surgical treatment in the Zhongnan Hospital of Wuhan University from January 2012 to December 2018. The median disease-free survival (DFS) and overall survival (OS) were calculated by Kaplan-Meier method. Cox regression was used to explore the prognostic factors. A total of 44 patients were included in our study. The median DFS was 25 months, 1- and 2-year DFS rate were 70.2% and 51.9%, respectively. The median OS was 41 months, 1- and 2- year OS rate were 88.4% and 69.9%, respectively. Multivariate analysis showed male (=6.56, =0.03), T3-4 (=6.23, =0.01), pathological lymph node metastasis (=6.52, =0.03) and adjuvant radiotherapy (=0.13, =0.002) were associated with disease relapse significantly. Moreover, pathological lymph node metastasis (=3.62, =0.01) coupled with sufficient adjuvant chemotherapy (≥4 cycles) (=0.12, =0.01) were independent prognostic factors of OS. Surgical therapy may be an alternative primary treatment for L-SCLC. Additional adjuvant radiotherapy can reduce the risk of recurrence. Giving sufficient course of adjuvant chemotherapy can improve OS.